IASO Bio Receives U.S. FDA Approval of Investigational New Drug Application for Equecabtagene Autoleucel for Multiple Sclerosis

SHANGHAI, NANJING, China and SAN JOSE, Calif., July 23, 2024 /PRNewswire/ — IASO Biotechnology (“IASO Bio”), a biopharmaceutical company dedicated to discovering, developing, manufacturing and commercializing innovative cell therapy and antibody products, announced that the…